Supplementary materials

Synthesis and Pharmacological Evaluation of (+)-Usnic Acid Derivatives as Hypoglycemic Agents

Table of contents

¹H, ¹³C, ¹⁹F NMR, IR and DFS spectra of compounds

Figures S1-S14

Chemistry

¹H and ¹³C NMR spectra were recorded in CDCl₃ with solvent resonances (H 7.24, C 76.90 ppm) as internal standards on a Bruker AV-400 spectrometer (operating frequency 400.13 MHz for ¹H and 100.61 MHz for ¹³C). Mass spectra (ionizing-electron energy 70 eV) were recorded on a DFS high-resolution mass spectrometer (Thermo Scientific). HPLC analyses were carried out on a MilichromA-02 using a ProntoSIL 120-5-C18 AQ column (BISCHOFF, 2.0 × 75 mm column, grain size 5.0 lm). The mobile phase used MeOH with 0.1% trifluoroacetic acid at a flow rate of 150 µL/min at 35 °C, with UV detection at 210, 220, 240, 260, 280, 300, 320 and 360 nm.

Compound 2 was synthesized from (+)-UA in according to [1] with the yield of 95%.



Figure S1. The ¹H NMR spectrum of compound 2.

Compound **3** was synthesized from (+)-UA in according to [2] with the yield of 70%.



Figure S2. The ¹H NMR spectrum of compound 3.

Compounds 4 and 5 were synthesized from (+)-UA in according to [3] with the yields of 87% each.



Figure S3. The ¹H NMR spectrum of compound 4.



Figure S4. The ¹H NMR spectrum of compound 5.



Figure S5. The ¹H NMR spectrum of compound 6.



Figure S6. The ¹³C NMR spectrum of 6





Figure S7. The ¹⁹F NMR spectrum of 6 (external standard C₆F₆)



Figure S8. The IR spectrum of 6



M⁺ calc m/z= 487.1237 (C25 H20 O6 N1 F3)⁺⁻ M⁺ meas m/z= 487.1238

Figure S9. The DFS spectrum of 6.



No	Time, µL	Height, AU	Area, AU* μL	Area, %
1	2589.16	0.03	0.885	1.63
2	2779.73	1.71	53.454	98.37

Figure S10. The HPLC spectrum of 6.



Figure S11. The ¹H NMR spectrum of compound 7.



Figure S12. The ¹³C NMR spectrum of 7



Figure S13. The IR spectrum of 7



Tsource=70°C

Tprobe=250°C

M⁺ calc m/z= 433.1520 (C25 H23 O6 N1) ⁺⁻ M⁺ meas m/z= 433.1521

Figure S14. The DFS spectrum of 7.